FDA Approves Defibrotide for Severe VOD Following Stem Cell Transplantation – OncLive
OncLive |
FDA Approves Defibrotide for Severe VOD Following Stem Cell Transplantation
OncLive The FDA has approved defibrotide sodium (Defitelio) as a treatment for severe hepatic veno-occlusive disease (VOD) with associated kidney or lung abnormalities following hematopoietic stem cell transplantation (HSCT), based on data from the collection … FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow |
